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Abstract
Scabies was adopted by the World Health Organization (WHO) as a
Neglected Tropical Disease in 2017. There is currently no formal global
scabies control programmes or existing WHO guidelines on scabies control
although at least two countries, Fiji and Ethiopia, have adopted national
approaches to scabies control. In February 2019 WHO held a first Informal
Consultation on a Framework for Scabies Control, in part as a response to
multiple national requests for guidance on public health management in
high disease burden areas. Below we outline control strategies proposed at
this meeting and summarise the role that modelling can play in supporting
the development of evidence to translate these proposals into formal WHO
recommendations and national and global control programmes. Provisional
proposals discussed at the WHO Informal Consultation for a scabies
control programme include the use of mass drug administration when the
community prevalence of scabies is ≥ 10% (generally considered to reflect
a childhood prevalence of at least 20%) and the use of intensified case
management when the prevalence is below 10%.
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Background
Scabies is caused by a microscopic mite (Sarcoptes scabiei 
var. hominis) (Chosidow, 2006). Female mites burrow into 
human skin to lay eggs. In classic scabies, the infestation – 
typically 5 to 15 female mites – and burrowing causes an 
allergic reaction in the host that triggers severe itching and pain 
that may interfere with everyday activities, including eating, 
sleeping, working and studying. Secondary skin lesions then 
develop, including papules, vesicles and nodules. Rarely, 
patients may develop crusted (previously known as ‘Norwegian’) 
scabies, which is characterised by plaques and extensive scales 
containing millions of mites. This form is highly infectious 
and associated with a high mortality.
Scabies is transmitted via direct human-to-human contact, 
making individuals living in overcrowded environments in the 
poorest of the world’s communities particularly susceptible to 
developing scabies. Scabies is not zoonotic and cannot be trans-
mitted to humans from dogs or other animals with mange. It 
is not waterborne and does not appear to be associated 
with poor hygiene. Skin conditions such as scabies are so 
common among children in some countries that parents may not 
consider a skin condition as a primary reason to seek medical 
treatment for their child.
Primary treatment in individual cases is usually topical and is 
often effective in resolving scabies in the patient. Of the exist-
ing topical agents, permethrin is probably the most effective 
treatment for scabies. Although topical treatments are effica-
cious, adherence can be compromised by skin irritation and 
inconvenience as they need to be applied to the whole body for 
8 hours or more. Ivermectin is a highly effective oral treat-
ment, and now approved for second-line use in several countries 
including France and Australia. There is also widespread expe-
rience utilising ivermectin as part of mass drug administration 
(MDA) for the control of other NTDs.
Several studies now indicate that MDA is an effective strategy 
for the control of scabies (Engelman et al., 2018). Studies using 
both topical and ivermectin-based MDA strategies have dem-
onstrated reductions in scabies prevalence of up to 90%. In the 
SHIFT randomised trial, conducted in Fiji (Romani et al., 2015), 
ivermectin-based MDA reduced the prevalence of scabies 
by 94% at 12 months. Similar results were seen in the AIM 
study in the Solomon Islands which enrolled more than 25,000 
participants who received ivermectin-based MDA (Romani 
et al., 2019a). Follow-up in these study sites at 24 and 36 months 
respectively demonstrate a sustained reduction in prevalence of 
both scabies and impetigo following MDA (Marks et al., 2019; 
Romani et al., 2019b).
Mathematical modelling of transmission and MDA
Modelling for scabies is in its infancy. Only a single paper 
(Lydeamore et al., 2019) has used a model incorporating mite 
life stages, and drug actions in relation to these stages, to 
explore questions related to the control of scabies. Lydeamore 
et al. used a mathematical model of scabies life-cycle and 
transmission dynamics in a homogeneously mixing population 
to simulate the impact of mass drug treatment strategies acting 
on egg and mite life cycle stages (ovicidal) or adult mites alone 
(non-ovicidal). Ovicidal interventions are currently based on 
topical treatments. While the model predicts that at high cover-
age rates the treatment strategies are highly effective, in practice 
these topical therapies are associated  with poor compliance.
For the non-ovicidal intervention (corresponding to the oral 
agent ivermectin), the model predicts that at least two opti-
mally-timed doses are required to achieve short term control. 
However, the model also demonstrates that rebound infection 
is inevitable following this strategy, even assuming optimal con-
ditions (100% efficacy, 100% coverage, no reimportation), due 
to residual persistence of eggs. Figure 1a demonstrates this 
point by showing the proportion of individuals who are infec-
tious (i.e. harbouring pregnant mites) after the first and 
second doses of therapy. The spike between doses is due to 
hatching eggs, justifying the need for the second dose. Figure 1b 
(right) shows the proportion with residual eggs, which does 
not reach zero even after two doses.
The model predicts that the likelihood of elimination is enhanced 
by repeated annual cycles of a multi-dose strategy, which drive 
down the proportion harbouring eggs over successive treatment 
courses. In this simplified system, a two dose schedule achieves 
50% likelihood of elimination after six years of implementation, 
and 80% after ten years (Figure 2). Further exploration in a more 
realistically configured population model is required to support 
policy.
What can modelling tell us about the currently 
proposed goals
Prior to 2020 there have been no established goals for scabies 
control but WHO proposes including targets related to sca-
bies in the next Neglected Tropical Disease (NTD) roadmap. 
Alongside incorporation of scabies into countries’ Universal 
Health Care plans, it is likely that ivermectin-based MDA will 
form a substantial component of the control strategy in many 
highly endemic countries. Modelling may help programmes 
to determine the optimal threshold for initiating and ceasing, 
and inform the optimal number and timing of MDA rounds.
Are there risks that need to be mitigated to achieve 
and maintain the stated goals?
The absence of any current scabies control programmes repre-
sents a major risk to eventual control of scabies. Unlike other 
NTD programmes for which MDA has been determined to 
be a key control strategy, there is no drug donation or fund-
ing scheme to support implementation of scabies control 
interventions programmatically. A strengthened evidence base 
to support WHO recommendations will increase the likeli-
hood of securing political and financial support for scabies 
control.
As with other NTD programmes, systematic non-participation 
in MDA may pose a barrier to control, although this has not 
been formally evaluated within the context of a scabies control 
programme. Modelling for other NTDs has shown that 
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Figure 1.  A total of 50 realisations of the Markov model (grey lines), using the Gillespie algorithm, compared with the mean-field approximation 
(black dotted line) with an MDA program consisting of two optimally timed non-ovicidal treatment doses on (a) the proportion of infected 
individuals and (b) the proportion of the population with eggs. Figure 1 has been reproduced with permission from Lydeamore MJ, Campbell 
PT, Regan DG, et al. A biological model of scabies infection dynamics and treatment informs mass drug administration strategies to increase 
the likelihood of elimination. Math Biosci 2019; 309:163–173.
Figure 2. Mean of 1000 simulations of the Markov chain, X(t), which experienced die-out for varying numbers of successive optimally 
timed non-ovicidal MDA treatments, with the program being repeated annually. Figure 2 has been reproduced with permission 
from Lydeamore MJ, Campbell PT, Regan DG, et al. A biological model of scabies infection dynamics and treatment informs mass drug 
administration strategies to increase the likelihood of elimination. Math Biosci 2019; 309:163–173.
non-participation can have a substantial effect on impact (Dyson 
et al., 2017). Current requirements for two doses of treat-
ment to be delivered during MDA might be anticipated to 
reduce participation. Future modelling work could determine 
the effect of systematic non-participation on the outcome of 
control interventions for scabies whilst ongoing trials will provide 
insight into whether a single dose MDA regime is sufficiently 
effective that it may be used in place of a two dose regime.
A small proportion of individuals with scabies may be highly 
infectious (crusted scabies). These individuals may not 
respond to treatment delivered as part of MDA and this might 
be anticipated to impact on the effectiveness of control pro-
grammes. Future modelling studies could be used to explore the 
impact that crusted scabies cases may have on the efficacy of 
MDA for scabies control.
Finally, in some settings, epidemics of scabies have been 
reported to be associated with changing climate conditions, par-
ticularly those leading to drought. Modelling could potentially 
explore whether global climate change is likely to contribute 
to a rise in the prevalence of scabies or frequency of large-scale 
outbreaks globally.
Future work
Control programmes and modelling for scabies are both in 
their infancy compared to many other NTD programmes. 
As such, there is considerable scope for modelling to play a 
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valuable role in refining the provisional framework for scabies 
control and in better estimating the global burden of disease 
related to scabies.
Modelling approaches will be of value in complementing 
empirical data in refining several elements of MDA implemen-
tation, including better defining the threshold at which MDA 
should be undertaken for the control of scabies, the level of 
coverage that must be attained to interrupt transmission, the 
threshold at which MDA should subsequently be stopped and 
exploring the optimal number of rounds of MDA to be under-
taken to achieve future programmatic goals. Current empirical 
data on the impact of MDA is predominantly from island 
populations, which may differ from non-island settings 
where scabies is a problem. Modelling may help understand 
differences and additional challenges in conducting MDA in these 
differing settings.
Secondly, current MDA recommendations include the use of 
permethrin for individuals unable to receive ivermectin, which 
results in significant logistical challenges. Age-structured mod-
els may allow formal evaluation of different MDA strategies 
(including choice of drug/s), necessary to justify the additional 
complexities of the proposed dual-therapy MDA programme. 
Evaluation of the potential impact of lowering the age of 
ivermectin administration from five to two years of age can 
also be explored within these frameworks. These approaches 
would be challenging to explore in trial situations due to the 
ethical considerations of not treating young children. Modelling 
will also have a role to play in predicting the likely impact 
and potential advantages of moxidectin as an agent for 
mass control of scabies, compared with currently available 
ivermectin.
As with other NTD programmes, heterogeneity in small area 
infection prevalence following MDA is noted within defined 
intervention zones. Modelling will allow evaluation of the 
importance of these heterogeneities to rebound of transmis-
sion between intervention rounds. In addition, the impact of 
repeated annual rounds of MDA administration on this hetero-
geneity will be explored, providing needed evidence to inform 
programme duration. Current empirical data is based entirely 
on MDA implementation in rural settings and modelling may 
help better understand the potential for differential impact of 
interventions in urban, peri-urban and rural settings.
Data availability
No data are associated with this article.
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